ArticlePsychiatry investigation2025
Global Burden of Depressive Disorders, 1990-2021, During the COVID-19 Pandemic and Projections to 2050: A Global Burden of Disease Study 2021.
Article in Psychiatry investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Global burden of depressive disorders from 1990 to 2021: temporal trends, COVID-19 Impact, and projections to 2050.European archives of psychiatry and clinical neuroscience · 2026Article
- Sex-based Differences in the Efficacy and Tolerability of Selective Serotonin Reuptake Inhibitors in Adults with Major Depressive Disorder: A Systematic Review and Meta-analysis.Indian journal of psychological medicine · 2026Review
- Psycho-cardiovascular interaction network in cardiovascular health and disease: signaling pathways and molecular mechanisms.Precision clinical medicine · 2026Review
- Decoupled Global Trends in Zinc Deficiency-attributable Burden (GBD CRA) and Depressive Disorders, 1990-2021: a GBD 2021 Analysis.Biological trace element research · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveDespite an increase in the depressive disorders burden during the coronavirus disease-2019 (COVID-19) pandemic, research remains insufficient. This study aims to advance the understanding of the global depressive disorders burden, focusing on the COVID-19 pandemic.
methodsGlobal and regional estimates of incidence, prevalence, and disability-adjusted life years (DALYs) for depressive disorders from 1990 to 2021 were analyzed using the Global Burden of Disease Study 2021. Depressive disorders were defined as the aggregate of major depressive disorder and dysthymia. Estimates were stratified by age, sex, Socio-demographic Index (SDI), and region, and trends were assessed by annual percent change. Attributable risk factors and projections to 2050 were assessed by modeling risk factors.
resultsIn 2021, depressive disorders accounted for 56,330.36 (95% uncertainty interval [UI], 39,339.99 to 76,538.17) DALYs. The age-standardized DALYs rate (ASDR) remained stable until 2019, followed by an increase during the COVID-19 pandemic (ASDR in 1990: 600.51 [95% UI, 420.94 to 818.45] per 100,000; in 2019: 593.50 [413.34 to 810.07]; in 2021: 681.14 [475.19 to 923.83]). The highest ASDRs were observed in low (837.53 [95% UI, 569.85 to 1,140.07] per 100,000) and low-middle (784.07 [542.47 to 1,059.21]) SDI regions. The burden increased rapidly among adolescents and remained higher in females than in males. The burden attributable to intimate partner violence increased during the COVID-19 pandemic. Projections suggest a modest decline in global ASDR, reaching 622.30 (95% UI, 430.96 to 847.82) per 100,000 by 2050.
conclusionThe global burden of depressive disorders increased sharply during the COVID-19 pandemic. It is essential to address regional disparities in mental health care and promote access to tailored treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.